Patient and disease characteristics of HSCT recipients
| . | Donor-derived VST . | Third-party VST . | Total no. of patients . |
|---|---|---|---|
| Sex | |||
| Male | 4 | 13 | 17 |
| Female | 3 | 7 | 10 |
| Median age at transplantation, y (range) | 12.79 (0.85-23.33) | 11.51 (1.08-63.32) | |
| Diagnosis | |||
| Malignancy | 2 | 12 | 14 |
| Immune deficiency | 4 | 5 | 9 |
| Marrow failure | 1 | 3 | 4 |
| Stem cell donor type | |||
| Related (MRD, MMRD, haploidentical) | 4 | 3 | 7 |
| Unrelated (MUD, MMUD) | 3 | 16 | 19 |
| Not available | 0 | 1 | 1 |
| Degree of HLA match | |||
| Full | 4 | 8 | 12 |
| Partial | 3 | 8 | 11 |
| Not available | 0 | 4 | 4 |
| Stem cell source | |||
| Bone marrow | 4 | 4 | 8 |
| PBSCs | 3 | 9 | 12 |
| Cord blood | 0 | 3 | 3 |
| Not available | 0 | 4 | 4 |
| Conditioning regimen | |||
| Myeloablative | 5 | 10 | 15 |
| Reduced intensity | 2 | 7 | 9 |
| Not available | 0 | 3 | 3 |
| GVHD prophylaxis (allo-HSCT only) | |||
| Calcineurin (cyclosporine A, tacrolimus) | 4 | 12 | 16 |
| Other (sirolimus + other) | 0 | 3 | 3 |
| Ex vivo T-cell depletion (CD34 selection) | 2 | 1 | 3 |
| Antithymocyte globulin | 0 | 1 | 1 |
| None | 1 | 3 | 4 |
| . | Donor-derived VST . | Third-party VST . | Total no. of patients . |
|---|---|---|---|
| Sex | |||
| Male | 4 | 13 | 17 |
| Female | 3 | 7 | 10 |
| Median age at transplantation, y (range) | 12.79 (0.85-23.33) | 11.51 (1.08-63.32) | |
| Diagnosis | |||
| Malignancy | 2 | 12 | 14 |
| Immune deficiency | 4 | 5 | 9 |
| Marrow failure | 1 | 3 | 4 |
| Stem cell donor type | |||
| Related (MRD, MMRD, haploidentical) | 4 | 3 | 7 |
| Unrelated (MUD, MMUD) | 3 | 16 | 19 |
| Not available | 0 | 1 | 1 |
| Degree of HLA match | |||
| Full | 4 | 8 | 12 |
| Partial | 3 | 8 | 11 |
| Not available | 0 | 4 | 4 |
| Stem cell source | |||
| Bone marrow | 4 | 4 | 8 |
| PBSCs | 3 | 9 | 12 |
| Cord blood | 0 | 3 | 3 |
| Not available | 0 | 4 | 4 |
| Conditioning regimen | |||
| Myeloablative | 5 | 10 | 15 |
| Reduced intensity | 2 | 7 | 9 |
| Not available | 0 | 3 | 3 |
| GVHD prophylaxis (allo-HSCT only) | |||
| Calcineurin (cyclosporine A, tacrolimus) | 4 | 12 | 16 |
| Other (sirolimus + other) | 0 | 3 | 3 |
| Ex vivo T-cell depletion (CD34 selection) | 2 | 1 | 3 |
| Antithymocyte globulin | 0 | 1 | 1 |
| None | 1 | 3 | 4 |
MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor.